{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T12:24:40Z","timestamp":1740140680479,"version":"3.37.3"},"reference-count":8,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T00:00:00Z","timestamp":1693785600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["10.13039\/100009945"],"award-info":[{"award-number":["10.13039\/100009945"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,10,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:label\/>\n                  <jats:p>In the phase III JAVELIN Ovarian 200 trial, 566 patients with platinum-resistant\/refractory ovarian cancer were randomized 1:1:1 to receive avelumab alone, avelumab plus pegylated liposomal doxorubicin (PLD), or PLD alone. Cardiac monitoring was included for all patients. We report left ventricular ejection fraction (LVEF) data from the trial. Grade\u2005\u22653 cardiac adverse events (AEs) occurred in 4 (2.1%), 1 (0.5%), and 0 patients in the avelumab, combination, and PLD arms, respectively. LVEF decreases of \u226510% to below institutional lower limit of normal at any time during treatment were observed in 1 (0.8%), 3 (1.9%), and 2 (1.5%) patients, respectively; 4 had subsequent assessments, and these showed transient decreases. No patient had a cardiovascular AE related to LVEF decrease. This analysis is, to our knowledge, the first analysis of LVEF in patients receiving immune checkpoint inhibitors.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>ClinicalTrials.gov Identifier<\/jats:title>\n                  <jats:p>NCT02580058.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/oncolo\/oyad213","type":"journal-article","created":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T19:10:33Z","timestamp":1693854633000},"page":"e977-e980","source":"Crossref","is-referenced-by-count":1,"title":["Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both"],"prefix":"10.1093","volume":"28","author":[{"given":"Marc P","family":"Bonaca","sequence":"first","affiliation":[{"name":"Colorado Prevention Center Clinical Research, Division of Cardiology, Department of Medicine, University of Colorado School of Medicine , Aurora, CO , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Javid J","family":"Moslehi","sequence":"additional","affiliation":[{"name":"Section of Cardio-Oncology and Immunology, Division of Cardiology and the Cardiovascular Research Institute, UCSF School of Medicine, Cardiovascular Research Institute (CVRI) , San Francisco, CA , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan A","family":"Ledermann","sequence":"additional","affiliation":[{"name":"UCL Cancer Institute and UCL Hospitals , London , UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabete","family":"Michelon","sequence":"additional","affiliation":[{"name":"Pfizer , New York, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caimiao","family":"Wei","sequence":"additional","affiliation":[{"name":"Pfizer , Groton, CT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Moran","sequence":"additional","affiliation":[{"name":"Pfizer Pharma GmbH , Berlin , Germany (Affiliation at the time the research was conducted)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley J","family":"Monk","sequence":"additional","affiliation":[{"name":"Arizona Oncology (US Oncology Network), University of Arizona and Creighton University , Phoenix, AZ , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Pujade-Lauraine","sequence":"additional","affiliation":[{"name":"ARCAGY-GINECO , Paris , France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,9,4]]},"reference":[{"issue":"12","key":"2023100311181886800_CIT0001","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/S1470-2045(18)30608-9","article-title":"Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study","volume":"19","author":"Salem","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9","key":"2023100311181886800_CIT0002","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S1470-2045(18)30457-1","article-title":"Immune checkpoint inhibitors and cardiovascular toxicity","volume":"19","author":"Lyon","year":"2018","journal-title":"Lancet Oncol"},{"volume-title":"Prescribing Information","year":"2022","author":"Bavencio (avelumab)","key":"2023100311181886800_CIT0003"},{"volume-title":"Summary of Product Characteristics","year":"2022","author":"Bavencio (avelumab)","key":"2023100311181886800_CIT0004"},{"issue":"7","key":"2023100311181886800_CIT0005","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"issue":"4","key":"2023100311181886800_CIT0006","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/0300891619839308","article-title":"Treatment of recurrent ovarian cancer with pegylated liposomal doxorubicin: a reappraisal and critical analysis","volume":"105","author":"Lorusso","year":"2019","journal-title":"Tumori"},{"issue":"13","key":"2023100311181886800_CIT0007","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"2023100311181886800_CIT0008","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s00280-019-03925-z","article-title":"Evaluation of the potential for QTc prolongation with avelumab","volume":"84","author":"Vugmeyster","year":"2019","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e977\/51821323\/oyad213.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/28\/10\/e977\/51821323\/oyad213.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T11:25:01Z","timestamp":1696332301000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/28\/10\/e977\/7259791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,4]]},"references-count":8,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,9,4]]},"published-print":{"date-parts":[[2023,10,3]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyad213","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2023,10,1]]},"published":{"date-parts":[[2023,9,4]]}}}